New Blood Cancer Treatment Gives Patients More Time

A groundbreaking immunotherapy combination helped 8 in 10 multiple myeloma patients live two years without their cancer getting worse, compared to just 5 in 10 with standard treatment.

The global trial involving over 860 patients offers renewed hope for those facing this difficult blood cancer.